Erenumab

Last updated

Erenumab
Aimovig Autoinjector.jpg
A standard 70mg/mL Aimovig autoinjector
Monoclonal antibody
Type Whole antibody
Source Human
Target CGRPR
Clinical data
Trade names Aimovig
Other namesAMG-334, erenumab-aooe
AHFS/Drugs.com Monograph
MedlinePlus a618029
License data
Pregnancy
category
Routes of
administration 		Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 82% (estimated)
Metabolism Proteolysis
Elimination half-life 28 days
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C6472H9964N1728O2018S50
Molar mass 145871.98 g·mol−1

Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. [3] [4] [5] It is administered by subcutaneous injection. [3] [4]

Contents

Erenumab, which was developed by Amgen and Novartis, [5] was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration. [6] In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [7] [8]

Medical uses

Erenumab is indicated for the prevention of migraine in adults. [3] [4]

Side effects

Common side effects are constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site. [4] [9]

Interactions

Erenumab was shown not to interact with ethinylestradiol, norgestimate or the migraine drug sumatriptan. It is expected to generally have a low potential for interactions because it is not metabolized by cytochrome P450 enzymes. [9]

Pharmacology

Mechanism of action

Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR). [3] [10] [11]

Pharmacokinetics

After subcutaneous injection, the erenumab has an estimated bioavailability of 82%. Highest blood plasma concentrations are reached after four to six days. Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids. It has an elimination half-life of 28 days. [9]

History

Erenumab was developed by Amgen Inc. in conjunction with Novartis. [5]

In the phase III STRIVE clinical trial 955 patients were divided into three groups in a 1:1:1 ratio. Each group was injected subcutaneously monthly with 0, 70 or 140 mg erenumab over a period of 6 months. The results were measured as mean monthly migraine days in months 4, 5, and 6. At baseline the patients experienced between 4 and 14 migraine days per month with an average of 8.3. The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group. [5] [12]

Society and culture

Economics

As of 2018, the list price was reported to be US$6,900 per year. [13]

In the United Kingdom, Erenumab was approved by the Scottish Medicines Consortium, but the National Institute for Health and Care Excellence rejected the drug on the basis that its cost-effectiveness was not sufficiently proven. [14] [15]

The United States Food and Drug Administration approved the medication for the preventive treatment of migraine in adults in May 2018. It was the first CGRPR antagonist to be approved. [6] It was approved for medical use in the European Union on 26 July 2018. [4] [16]

Names

Erenumab is the international nonproprietary name and the United States Adopted Name. [17] [18]

Related Research Articles

<span class="mw-page-title-main">Sumatriptan</span> Medication used for migraines & cluster headaches

Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. It is taken orally, intranasally, or by subcutaneous injection. Therapeutic effects generally occur within three hours.

<span class="mw-page-title-main">Rizatriptan</span> Medication used for the treatment of migraine headaches

Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches. It is taken by mouth. It can also be applied on the tongue. It is a serotonin (5-HT) 1B/1D receptor agonist (triptan).

<span class="mw-page-title-main">Insulin glargine</span> Long-acting insulin

Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. It is injected just under the skin. Effects generally begin an hour after use.

<span class="mw-page-title-main">Enoxaparin sodium</span> Anticoagulant medication (blood thinner)

Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication. It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.

<span class="mw-page-title-main">Calcitonin gene-related peptide</span> Peptide hormone in animals

Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, adrenomedullin, adrenomedullin 2 (intermedin) and calcitonin‑receptor‑stimulating peptide. Calcitonin is mainly produced by thyroid C cells whilst CGRP is secreted and stored in the nervous system. This peptide, in humans, exists in two forms: CGRP alpha, and CGRP beta. α-CGRP is a 37-amino acid neuropeptide and is formed by alternative splicing of the calcitonin/CGRP gene located on chromosome 11. β-CGRP is less studied. In humans, β-CGRP differs from α-CGRP by three amino acids and is encoded in a separate, nearby gene. The CGRP family includes calcitonin (CT), adrenomedullin (AM), and amylin (AMY).

<span class="mw-page-title-main">Ofatumumab</span> Medication

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.

<span class="mw-page-title-main">Insulin lispro</span> Rapid-acting insuline analog

Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is delivered subcutaneously either by injection or from an insulin pump. Onset of effects typically occurs within 30 minutes and lasts about 5 hours. Often a longer-acting insulin like insulin NPH is also needed.

<span class="mw-page-title-main">Liraglutide</span> Anti-diabetic medication

Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. It is a second-line therapy for diabetes following first-line therapy with metformin. Its effects on long-term health outcomes like heart disease and life expectancy are unclear. It is given by injection under the skin.

<span class="mw-page-title-main">Afamelanotide</span> Chemical compound

Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria. It is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant.

<span class="mw-page-title-main">Linagliptin</span> Chemical compound

Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes in conjunction with exercise and diet. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.

Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight loss.

Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

<span class="mw-page-title-main">Galcanezumab</span> Monoclonal antibody

Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for the treatment of cluster headaches.

Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by injection under the skin.

Pegvaliase, sold under the brand name Palynziq, is a medication used for the treatment of the genetic disease phenylketonuria (PKU). It is a phenylalanine (Phe)‑metabolizing enzyme. Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.

Peter Goadsby is an Australian neuroscientist who is Director of the National Institute for Health Research - Wellcome Trust King’s Clinical Research Facility and Professor of Neurology at King's College London. His research has focused particularly on the mechanism and alleviation of migraine and cluster headaches.

<span class="mw-page-title-main">Zilucoplan</span> Chemical compound

Zilucoplan, sold under the brand name Zilbrysq, is a medication used for the treatment of generalized myasthenia gravis. It is a complement inhibitor that is injected subcutaneously.

References

  1. ↑ "Erenumab (Aimovig) Use During Pregnancy". Drugs.com. 17 April 2019. Archived from the original on 29 November 2020. Retrieved 5 May 2020.
  2. ↑ "Summary Basis of Decision (SBD) for Aimovig". Health Canada . 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  3. 1 2 3 4 5 "Aimovig- erenumab-aooe injection Aimovig- erenumab-aooe injection, solution". DailyMed. 19 August 2022. Archived from the original on 5 July 2022. Retrieved 29 September 2022.
  4. 1 2 3 4 5 6 "Aimovig EPAR". European Medicines Agency (EMA). 8 August 2018. Archived from the original on 17 October 2020. Retrieved 4 May 2020.
  5. 1 2 3 4 Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. (November 2017). "A Controlled Trial of Erenumab for Episodic Migraine". The New England Journal of Medicine. 377 (22): 2123–2132. doi: 10.1056/NEJMoa1705848 . PMID   29171821.
  6. 1 2 "FDA Approves First-in-Class Drug Erenumab (Aimovig) for Migraine Prevention". Medscape . 17 May 2018. Archived from the original on 25 September 2019. Retrieved 21 May 2018.
  7. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  8. ↑ "Erenumab - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  9. 1 2 3 "Aimovig: EPAR - Product Information" (PDF). European Medicines Agency. 8 August 2018. Archived (PDF) from the original on 6 October 2018. Retrieved 2 May 2019.
  10. ↑ "Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig (erenumab) For Migraine Patients With Multiple Treatment Failures" (Press release). Amgen. 17 April 2018. Archived from the original on 11 November 2020. Retrieved 29 September 2022– via PR Newswire.
  11. ↑ Edvinsson L (December 2018). "CGRP Antibodies as Prophylaxis in Migraine". Cell. 175 (7): 1719. doi: 10.1016/j.cell.2018.11.049 . PMID   30550780.
  12. ↑ "Erenumab to prevent migraine: results from phase III STRIBE" Archived 13 August 2018 at the Wayback Machine , Pharma World, 14 December 2017.
  13. ↑ Kolata G (17 May 2018). "F.D.A. Approves First Drug Designed to Prevent Migraines". The New York Times . Archived from the original on 11 May 2020. Retrieved 26 September 2019.
  14. ↑ Gallagher J (26 September 2019). "'Life-changing' migraine drug rejected for NHS". BBC News Online . Archived from the original on 31 July 2021. Retrieved 26 September 2019.
  15. ↑ "New migraine drug not cost-effective NICE says in draft guidance". NICE. Archived from the original on 1 November 2020. Retrieved 26 September 2019.
  16. ↑ "First drug to prevent chronic migraines approved by EU". The Guardian . 31 July 2018. Archived from the original on 19 September 2018. Retrieved 19 September 2018.
  17. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Erenumab" (PDF). American Medical Association. 24 November 2015. Archived (PDF) from the original on 4 November 2018. Retrieved 4 November 2018.
  18. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 30 September 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.